Largest review of clinical trials to assess risk of patients using Varenicline

Findings from the largest review of clinical trials to date to determine whether patients prescribed the smoking cessation drug Varenicline (brand name Champix in the UK) are at an increased risk of neuropsychiatric events are have been published.



from Today's Healthcare News -- ScienceDaily http://ift.tt/1GJAgie